De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

PurposeDespite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially non-small cell lung cancer (NSCLC), the clinical significance of ROS1 de novo mutation has not yet been understood. We sought to elucidate the predictive effect of ROS1 mutation for immune checkp...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Si-Cong Ma, Hong-Bo Zhu, Jian Wang, Yan-Pei Zhang, Xue-Jun Guo, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Zhong-Yi Dong, Xue Bai
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-06-01
coleção:	Frontiers in Oncology
Assuntos:	ROS1 mutation immune checkpoint inhibitor melanoma tyrosine kinase domain tumor mutational burden
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2021.666145/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!